We are committed to enabling you make things better. We love finding ways to create plant-based products with superior results. We team up with companies to make a big splash in the market.
You want to create something special that performs well, sells well and respects nature. With so many rules, costs, and competitors, it's tough to know which way to go.
Itaconix produces key ingredients for new generations of safer consumer products with superior performance and sustainability.
Every day we are motivated by the vision of biology powering the change humankind so desperately needs. Itaconix is leading that revolution.
We are building a large, profitable specialty ingredient company with safer products for the low carbon economy. Our growth rate has just begun to tap the potential of the addressable market.
Itaconix has entered a new era of development toward our long-term goal of becoming a large, highly profitable, capital-efficient specialty-ingredient company.
We know how to leverage our knowledge and expertise to offer insights that few others can.
Subscribe for updates and get insights sent directly to your inbox.
We have delivered revenues in line with market expectations at $7.9m, representing 40.5% growth when compared to revenues of $5.6m in FY2022.
We also continued to improve our gross margin percentage, reduce our adjusted EBITDA losses, and make substantial operational and financial progress as outlined below.
| The total number of Itaconix plc securities in issue: | 13,486,122 |
|---|---|
| The percentage of securities not in public hands is: | 24.7% |
| Details of any other exchanges or trading platforms: | The company's shares can be traded on the OTCQB. (OTCQB: ITXXF) |
| Country of incorporation: | United Kingdom |
| Main country of operation: | United States of America |
This information was last updated on 31 March 2024
As of 30 June 2024, Itaconix had been notified of the following holdings comprising more than three per cent of the share capital of the company: subsequent notifications received from major shareholders and PDMRs are shown in the Regulatory Announcements section of the website.
| Name | # of Ordinary Shares | % of Issued Share Capital |
|---|---|---|
| Hargreaves Lansdown Asset Management | 1,799,908 | 13.4% |
| Octopus Investment | 1,447,146 | 10.7% |
| Canaccord Genuity Wealth Management | 1,186,140 | 8.8% |
| IP Group | 1,118,262 | 8.3% |
| John R. Shaw | 1,081,441 | 8.0% |
| Amati Global Investors | 784,313 | 5.8% |
| Interactive Investor | 767,602 | 5.7% |
| Rathbones | 500,397 | 3.7% |
| HSLD Stockbrokers | 492,408 | 3.7% |
| AJ Bell Stockbrokers | 440,861 | 3.3% |
| Itaconix Plc Directors & Related Holdings | 412,196 | 3.1% |
Details of any other exchanges or trading platforms:The company’s shares can be traded on the OTCQB. (OTCQB: ITXXF)
Details of any restrictions on the transfer of its AIM securities: There are no restrictions on the transfer of securities.
Subscribe to our blog to get insights sent directly to your inbox.